News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarin Corporation PLC (AMRN) Announces Publication of Additional Inflammatory Marker Data From MARINE and ANCHOR Phase 3 Clinical Trials in the American Journal of Cardiovascular Drugs



1/22/2013 9:12:24 AM

BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE and ANCHOR Phase 3 clinical trials are now available electronically through PubMed (available at: http://www.ncbi.nlm.nih.gov/pubmed/23325450) and are expected to be published in the print issue of the American Journal of Cardiovascular Drugs in February 2013.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES